Users Stopping Anti-Obesity Jabs Put On Weight Far More Rapidly Compared to Those on Conventional Diets

A recent study suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end conventional lifestyle programs.

Research printed in a leading medical journal points out that while overweight people frequently drop substantial amounts of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.

"People using such medications should be informed of the risk of fast rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.

That rate of recovery implies a reversion to original weight in about a year and a half.

Comparing Therapies

The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with other pills.

The team note that individuals who shed pounds through dieting typically have a slower creep back—perhaps 100 grams monthly—post-intervention.

Explaining the Rapid Regain

Experts believe the mode of action of the drugs is key to understanding the amplified rebound.

The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.

"Withdrawal of this medication results in appetite is no longer kept in check, making excessive eating far more likely."

A Chronic Condition?

The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.

Professionals say that, given the high risk of relapse, the therapy might need to be long-term.

This perspective is echoed by drug manufacturers, who note that the results "emphasize the long-term character of obesity," comparing it to managing conditions like high blood pressure.

Patient Experiences

Users who have stopped the jabs describe a powerful resurgence of hunger.

"It was like something flipping and you become starving," described an individual.

This difficulty is compounded if users have not developed sustainable dietary or behavioural modifications during therapy.

Significant Adoption

Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest remaining high.

• Adoption is more common among females than men.
• The middle-aged demographic shows the greatest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Finally, clinicians caution that while the jabs are powerful tools for shedding pounds, they are not a permanent solution and long-term success relies on combined behavioural support.